Back
Argan, Inc. 10K Form
Buy
70
AGX
Argan, Inc.
Last Price:
$355.52
Seasonality Move:
7.33%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-06-06 | 10Q | AGX/Argan, Inc. Quarterly |
| 2023-12-06 | 10Q | AGX/Argan, Inc. Quarterly |
| 2023-09-06 | 10Q | AGX/Argan, Inc. Quarterly |
| 2023-06-08 | 10Q | AGX/Argan, Inc. Quarterly |
| 2022-12-07 | 10Q | AGX/Argan, Inc. Quarterly |
| 2022-09-08 | 10Q | AGX/Argan, Inc. Quarterly |
Receive AGX News And Ratings
See the #1 stock for the next 7 days that we like better than AGX
AGX Financial Statistics
Sales & Book Value
| Annual Sales: | $874.2M |
|---|---|
| Cash Flow: | $32.9M |
| Price / Cash Flow: | 35.83 |
| Annual Sales: | $28.47 |
| Price / Book: | 12.52 |
Profitability
| EPS (TTM): | 8.30930 |
|---|---|
| Net Income (TTM): | $117.2M |
| Gross Margin: | $142.5M |
| Return on Equity: | 33.57% |
| Return on Assets: | 14.53% |
Argan, Inc. Earnings Forecast
Key Argan, Inc. Financial Ratios
-
The Gross Profit Margin over the past 37 years for AGX is 16.30%.
-
The Selling, General & Administrative Expenses for AGX have been equal to 6.04% of Gross Profit Margin.
-
The Research & Development expenses have been 0.00% of Revenue.
-
The Interest Expense is 0.00% of Operating Income.
-
The Net Earning history of AGX is 9.78% of Total Revenues.
-
Per Share Earnings over the last 37 years have been positive in 20 years.
Argan, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NYSE |
|---|---|
| Industry: | Construction & Engineering |
| Sector: | Industrials |
| Current Symbol: | AGX |
| CUSIP: | 04010E |
| Website: | arganinc.com |
Debt
| Debt-to-Equity Ratio: | 0.01 |
|---|---|
| Current Ratio: | 1.71 |
| Quick Ratio: | 1.6 |
Price-to-Earnings
| Trailing P/E Ratio: | 57.99 |
|---|---|
| Forward P/E Ratio: | 35.39 |
AGX Technical Analysis vs Fundamental Analysis
Buy
70
Argan, Inc. (AGX)
is a Buy
Is Argan, Inc. a Buy or a Sell?
-
Argan, Inc. stock is rated a BuyThe current Argan, Inc. [AGX] share price is $356.39. The Score for AGX is 70, which is 40% above its historic median score of 50, and infers lower risk than normal.